- Flow Perturbation Mediates Neutrophil Recruitment and Potentiates Endothelial Injury via TLR2 in Mice - Implications for Superficial Erosion. [Journal Article]
- CircRCirc Res 2017 Apr 20
- CONCLUSIONS: These results implicate flow disturbance, neutrophils, and TLR2 signaling as mechanisms that contribute to superficial erosion, a cause of ACS of likely growing importance in the statin era.
- A Possible Early Biomarker for Bicuspid Aortopathy: Circulating Transforming Growth Factor Beta-1 to Soluble Endoglin Ratio. [Journal Article]
- CircRCirc Res 2017 Apr 18
- CONCLUSIONS: The novel evidence of a possible value of the T/E ratio as a biomarker of BAV aortopathy was presented: further validation studies are warranted.
- Hypercholesterolemia Induces Differentiation of Regulatory T Cells in the Liver. [Journal Article]
- CircRCirc Res 2017 Apr 18
- CONCLUSIONS: Our results elucidate a new mechanism that controls intrahepatic T cell differentiation during atherosclerosis development and indicates that intrahepatically differentiated T cells contribute to the CD4+ T cell pool in the atherosclerotic aorta.
- Correction to: β-Adrenergic Signaling Inhibits Gq-Dependent Protein Kinase D Activation by Preventing Protein Kinase D Translocation and Multimodal SHG-2PF Imaging of Microdomain Ca(2+)-Contraction Coupling in Live Cardiac Myocytes. [Journal Article]
- CircRCirc Res 2017 Apr 14; 120(8):e32
- Correction to: Identification of a Retinal Aldosterone System and the Protective Effects of Mineralocorticoid Receptor Antagonism on Retinal Vascular Pathology. [Journal Article]
- CircRCirc Res 2017 Apr 14; 120(8):e31
- Cell Therapy Trials in Congenital Heart Disease. [Review]
- CircRCirc Res 2017 Apr 14; 120(8):1353-1366
- Dramatic evolution in medical and catheter interventions and complex surgeries to treat children with congenital heart disease (CHD) has led to a growing number of patients with a multitude of long-t...
Dramatic evolution in medical and catheter interventions and complex surgeries to treat children with congenital heart disease (CHD) has led to a growing number of patients with a multitude of long-term complications associated with morbidity and mortality. Heart failure in patients with hypoplastic left heart syndrome predicated by functional single ventricle lesions is associated with an increase in CHD prevalence and remains a significant challenge. Pathophysiological mechanisms contributing to the progression of CHD, including single ventricle lesions and dilated cardiomyopathy, and adult heart disease may inevitably differ. Although therapeutic options for advanced cardiac failure are restricted to heart transplantation or mechanical circulatory support, there is a strong impetus to develop novel therapeutic strategies. As lower vertebrates, such as the newt and zebrafish, have a remarkable ability to replace lost cardiac tissue, this intrinsic self-repair machinery at the early postnatal stage in mice was confirmed by partial ventricular resection. Although the underlying mechanistic insights might differ among the species, mammalian heart regeneration occurs even in humans, with the highest degree occurring in early childhood and gradually declining with age in adulthood, suggesting the advantage of stem cell therapy to ameliorate ventricular dysfunction in patients with CHD. Although effective clinical translation by a variety of stem cells in adult heart disease remains inconclusive with respect to the improvement of cardiac function, case reports and clinical trials based on stem cell therapies in patients with CHD may be invaluable for the next stage of therapeutic development. Dissecting the differential mechanisms underlying progressive ventricular dysfunction in children and adults may lead us to identify a novel regenerative therapy. Future regenerative technologies to treat patients with CHD are exciting prospects for heart regeneration in general practice.
- Bioresorbable Scaffold: The Emerging Reality and Future Directions. [Review]
- CircRCirc Res 2017 Apr 14; 120(8):1341-1352
- In the era of drug-eluting stents, large-scale randomized trials and all-comer registries have shown excellent clinical results. However, even the latest-generation drug-eluting stent has not managed...
In the era of drug-eluting stents, large-scale randomized trials and all-comer registries have shown excellent clinical results. However, even the latest-generation drug-eluting stent has not managed to address all the limitations of permanent metallic coronary stents, such as the risks of target lesion revascularization, neoatherosclerosis, preclusion of late lumen enlargement, and the lack of reactive vasomotion. Furthermore, the risk of very late stent, although substantially reduced with newer-generation drug-eluting stent, still remains. These problems were anticipated to be solved with the advent of fully biodegradable devices. Fully bioresorbable coronary scaffolds have been designed to function transiently to prevent acute recoil, but have retained the capability to inhibit neointimal proliferation by eluting immunosuppressive drugs. Nevertheless, long-term follow-up data of the leading bioresorbable scaffold (Absorb) are becoming available and have raised a concern about the relatively higher incidence of scaffold thrombosis. To reduce the rate of clinical events, improvements in the device, as well as implantation procedure, are being evaluated. This review will focus on the current CE-mark approved bioresorbable scaffolds, their basic characteristics, and clinical results. In addition, we summarize the current limitations of bioresorbable scaffold and their possible solutions.
- Why Don't We Have Proven Treatments for HFpEF? [Journal Article]
- CircRCirc Res 2017 Apr 14; 120(8):1243-1245
- Rigor and Reproducibility in Analysis of Vascular Calcification. [Journal Article]
- CircRCirc Res 2017 Apr 14; 120(8):1240-1242
New Search Next
- Proliferative Versus Degenerative Paradigms in Pulmonary Arterial Hypertension: Have We Put the Cart Before the Horse? [Journal Article]
- CircRCirc Res 2017 Apr 14; 120(8):1237-1239